22.02.2016

ARS regulatory team submitted a clinical trial approval application for a Phase II randomized open-label study of reactogenicity and immunogenicity of a vaccine against Shigella flexneri. A Russian biotech company will sponsor this project. 120 patients will be recruited at two sites in Russia.